Previous 10 | Next 10 |
2024-04-29 16:31:44 ET More on Terns Pharmaceuticals Terns Pharmaceuticals appoints Melita Sun Jung as chief business officer Terns to report Phase 1 data on GLP-1 drug in 2H 2024 Seeking Alpha’s Quant Rating on Terns Pharmaceuticals Historical earning...
2024-04-29 12:47:40 ET More on Amgen Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Amgen’s Blincyto data send Cullinan higher AbbVie k...
2024-04-28 20:52:48 ET More on MorphoSys MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript Novartis And MorphoSys Are A Perfect Match Novartis commences tender offer for MorphoSys MorphoSys gains after gaining U.S. antitrust approval for sale to Novartis ...
2024-04-28 13:00:22 ET Orphan drugs -- medicines to treat rare diseases -- from Johnson & Johnson ( NYSE: JNJ ), Roche ( OTCQX:RHHBY ), and AstraZeneca ( NASDAQ: AZN ) will allow these companies to reign as the top 3 orphan drugmakers, by sales, in 2028.... Rea...
2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...
2024-04-27 07:00:00 ET Summary Attempting to time the market is not a successful strategy. Long-term investing has consistently outperformed market timing. Today, the S&P is fairly valued, but blue-chip bargains are plentiful if you know where to look. These 16 dividend ar...
2024-04-26 15:56:40 ET Summary Shares of Deciphera Pharmaceuticals, Inc. have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT. Vimseltinib is expected to make significant progress in the TGCT indication, as the only approved therapy is ...
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
2024-04-23 18:25:09 ET Scooting past analyst estimates for its latest quarter gave Novartis (NYSE: NVS) a lift on Tuesday. Investors like what they heard about the global healthcare company's inaugural earnings release for 2024, and rewarded Novartis with a more than 2% lift in its ...
2024-04-23 15:00:03 ET Wan Nurhayati from CFRA issued a price target of $108.00 for NVS on 2024-04-23 13:11:00. The adjusted price target was set to $108.00. At the time of the announcement, NVS was trading at $97.27. NVS currently trades -10.58% versus its 52 week high ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...